

Harvest is commercializing, internationally, the first and only technology that makes it possible for physicians to derive adult stem cells from their patient at the point of care in just 15 minutes.



Wes Verkaar
Co-Founder

"Using our BMAC System, European doctors are able to offer an option to patients with Critical Limb Ischemia to avoid amputation."



P. Kevin Benoit, GM
Strategic Business Relations

"Autologous adult stem cells from bone marrow are of great interest to researchers. The markets for our BMAC System are quite large."



Andrew McGillicuddy
Chief Financial Officer

"There hasn't been a simple, rapid system for concentrating adult stem cells from a tiny volume of bone marrow at the point of care."



Frank Stephenson
VP, Marketing & Sales

"Concentrating bone marrow-derived adult stem cells at a patient's bedside is the ultimate in convenience for both the doctor and his patient."

"Should we use *embryonic* stem cells or *adult* stem cells for future medical therapies? ... Whoever would cure, must use adult stem cells ... science should concentrate on research with adult stem cells and renounce further experiments with the embryonic."

Wolfgang Lillge, M.D., Editor-in-Chief, *FUSION*, Sept./Oct. 2001 Issue

Stemming diseases

By Ronald C. Trahan

There are 20 *published* clinical studies involving 1,483 patients at 36 sites worldwide offering compelling evidence that *adult stem cells derived from autologous bone marrow* enable clinicians to offer new therapies for a variety of serious diseases.

Harvest[®] has received clearance in Europe to concentrate the cellular components from bone marrow via its breakthrough **BMAC™** (Bone Marrow Aspirate Concentrate) System, currently being used in Europe to treat vascular, orthopedic and cardiovascular diseases—the first and only product that makes possible the use of a clinically effective quantity of cellular compositions from a small aspirate of autologous bone marrow, which includes a large quantity of adult stem cells, derived from a patient at point-of-care in just 15 minutes.

"With further clinical validation, the Harvest technology may offer us the possibility of harvesting a quick, simple and clinically effective stem cell concentration from a patient at the point of care to treat, for example, his vascular disease," says Thomas F. O'Donnell, M.D., Senior Surgeon, Vascular Surgery Division, Tufts-New England Medical Center and a

scientific advisor to Harvest Technologies.

A multicenter U.S. clinical study using the BMAC System is planned to be underway soon targeting patients with *Critical Limb Ischemia (CLI)*, the later stage of *Peripheral Arterial Disease (PAD)*—clogged arteries, particularly in the lower legs. Patients with CLI are at extreme risk for major amputation. Reportedly, some 500,000 people worldwide



"Autologous adult stem cells from bone marrow offer profound potential as therapies—but they are hard to find with the techniques used to date."
Gary Tureski,
President
Harvest Technologies

suffer from CLI, and about 160,000 amputations are performed each year in the U.S. as a result of this condition (source: The Sage Group).

"By providing autologous adult stem cells immediately at the time of the bone marrow aspiration, our Harvest device may facilitate the practical application of stem cell therapy for CLI patients," adds Tureski. ■